Drug eluting stents have become an important component in percutaneous treatment of patients with symptomatic coronary artery disease. Drug eluting stents have been used more frequently in patient presented with acute coronary syndrome. However, this population is high risk patients and compared with elective patients, stent related outcomes may vary. In this study, everolimus eluting stent (XIENCE V) implantations and follow up results in patients presented with ACS were evaluated. 126 ACS patients who underwent everolimus eluting stent deployment for coronary artery lesions in Hacettepe University Faculty of Medicine Department of Cardiology included. Baseline demographic, clinic and angiographic data, procedure related complications and outcomes during follow up were studied. As primary endpoints all-cause mortality was %4,0 and target lesion failure was %4,8. As secondary outcomes, cardiac death, target leson revascolarization, target vessel revascularization, myocardial infarction and major adverse cardiovascular events were seen %2,4, %0,8, %4,0, %2,4 ve %10,3, respectively. There is no stent thrombosis case in this population. All outcomes except for TLR and stent thrombosis were seen more frequently than elective patients. When further evaluate, cerebrovascular accident and premature discontinuation of dual antiplatelet therapy were strong predictors of total mortality. These results demonstrate decreased effectiveness and safety of the XIENCE V everolimus eluting stent in ACS patient and caution should be exercised in these patients.